Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...
Zenshine Pharmaceuticals
Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA
On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule...
Nanjing Zenshine’s ZX-7101A NDA Accepted by NMPA for Uncomplicated Influenza Treatment
Nanjing Zenshine Pharmaceuticals Co., Ltd., a China-based small molecule drug developer, has announced that the...
Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...
Nanjing Zenshine Pharmaceuticals’ ZX-7101A Meets Primary Endpoint in Phase II Influenza Study
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd announced that a Phase II...
Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...